The Serum Institute of India (SII) On November 26 resumed the export of Covishield, a made-in-India vaccine against Covid-19. The export service has been resumed under the global vaccine sharing programme namely 'COVAX', reported PTI. ''The first batches of the vaccine left the SII manufacturing facility in Pune,'' said the company. So far, the SII produced close to 1.25 billion vaccine doses.
Courtesy: Press Trust Of India
The Serum Institute of India is planning to launch another COVID-19 vaccine 'Covovax' by August 2021. Developed by Novavax, an American vaccine maker, the Covovax will be stockpiled by the SII, for its testing on the Indian population, starting from April. Speaking at the Bloomberg Equity Index, SII CEO Adar Poonawalla said Covovax distribution will start after receiving the government’s nod. Poonawalla added that the global COVAX facility is… read-more
Courtesy: The Indian Express
West-African country Ghana became the first country to obtain vaccines under the COVAX initiative as it welcomed 6,00,000 doses of the AstraZeneca vaccine by Serum Institute of India on February 24. Delivered by UNICEF, the vaccines reached Ghana’s Kotoka International Airport as part of the initial wave of COVID-19 vaccines that COVAX is granting to 92 low/middle-income nations. Reportedly, Ghana’s will commence its phased vaccination drive… read-more
Courtesy: The Hindu